Search by Drug Name or NDC
NDC 66215-0718-01 UPTRAVI 1800 ug/10mL Details
UPTRAVI 1800 ug/10mL
UPTRAVI is a INTRAVENOUS INJECTION, POWDER, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Actelion Pharmaceuticals US, Inc.. The primary component is SELEXIPAG.
MedlinePlus Drug Summary
Selexipag injection is used in adults who are taking selexipag tablets to treat pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs) but are temporarily unable to take medications by mouth. Selexipag injection is in a class of medications called selective nonprostanoid IP prostacyclin receptor agonists. It works by relaxing the blood vessels in the lungs to allow blood to flow easily.
Related Packages: 66215-0718-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Selexipag Injection
Product Information
NDC | 66215-0718 |
---|---|
Product ID | 66215-718_f9b62ce2-37c1-2e5c-e053-6394a90a657b |
Associated GPIs | 40120070002120 |
GCN Sequence Number | 082563 |
GCN Sequence Number Description | selexipag VIAL 1800 MCG INTRAVEN |
HIC3 | B1C |
HIC3 Description | PULMONARY ANTIHYPERTENSIVES, PROSTACYCLIN-TYPE |
GCN | 50017 |
HICL Sequence Number | 042922 |
HICL Sequence Number Description | SELEXIPAG |
Brand/Generic | Brand |
Proprietary Name | UPTRAVI |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Selexipag |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, POWDER, FOR SOLUTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 1800 |
Active Ingredient Units | ug/10mL |
Substance Name | SELEXIPAG |
Labeler Name | Actelion Pharmaceuticals US, Inc. |
Pharmaceutical Class | Prostacyclin Receptor Agonist [EPC], Prostacyclin Receptor Agonists [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA214275 |
Listing Certified Through | 2024-12-31 |
Package
NDC 66215-0718-01 (66215071801)
NDC Package Code | 66215-718-01 |
---|---|
Billing NDC | 66215071801 |
Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (66215-718-01) / 10 mL in 1 VIAL, SINGLE-DOSE |
Marketing Start Date | 2021-07-29 |
NDC Exclude Flag | N |
Pricing Information | N/A |